.svg)
Two Oxford-based healthcare data leaders, Arcturis Data and Akrivia Health, have agreed terms on a £140m all-share merger aimed at establishing a dominant sovereign British medical analytics platform. The combined entity will aggregate clinical records from 40 National Health Service trusts, establishing direct access to data from over 20 million active patients and an overall archive exceeding 100 million anonymised files. Final completion of the transaction is scheduled for the autumn, consolidating substantial clinical assets to supply multinational pharmaceutical developers with real-world research evidence.
Daily Dazzling Dawn understands that institutional investors and internal operational teams across both Oxford enterprises received formal briefings regarding the transaction terms earlier this week. The unified enterprise will function as the United Kingdom’s largest domestic real-world healthcare analytics repository, retaining legal incorporation, operational infrastructure, and data governance entirely within British borders.
Specialist research divisions within the combined group will focus on five core clinical domains: oncology, neurology, immunology, cardiovascular disorders, and psychiatric conditions. Both firms already maintain extensive research collaborations with major pharmaceutical manufacturers, including AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Bristol Myers Squibb, Novartis, and Teva Pharmaceutical Industries. Senior market participants speaking to Daily Dazzling Dawn noted that the enlarged enterprise creates a comprehensive domestic alternative capable of supporting early-stage drug discovery and long-term epidemiological tracking across the British health sector.
The consolidation occurs amid heightened parliamentary and public scrutiny surrounding the expanding presence of US software corporation Palantir Technologies across public sector departments. Central government expenditure forecasts for the NHS England Federated Data Platform developed by Palantir recently escalated toward £1.1bn, coinciding with revised independent projections that reduced anticipated commercial efficiencies.
Palantir has concurrently faced sustained scrutiny over analytics contracts awarded by the Metropolitan Police Service, drawing formal inquiries from the Mayor of London, Sir Sadiq Khan. Within this operating environment, industry analysts close to the Oxford transaction observed to journalists that the creation of a domestic aggregator directly addresses institutional demands for sovereign governance over NHS digital assets.
For Arcturis Data, the transaction represents an important consolidation phase following substantial corporate restructuring over the past four years. Originally founded as Sensyne Health by former science minister Lord Drayson, the firm averted administration in 2022 through a £26m recapitalisation programme led by former Lansdowne Partners and Oxford Science Enterprises chief executive Alex Snow.
Arcturis subsequently secured an additional £10m growth financing round backed by Salica Investments and Lansdowne Partners. In tandem, Akrivia Health emerged in 2019 as an academic spinout developed in partnership with the University of Oxford and NHS clinical bodies, utilising the proprietary Clinical Record Interactive Search platform to process complex psychiatric and neurological records.
While definitive board appointments will be formalised closer to autumn completion, Daily Dazzling Dawn learned that Akrivia chief executive David Newton and Arcturis executive Alex Snow will occupy senior leadership offices within the unified corporate structure.
